Eyenovia, Inc. (EYEN)
| Market Cap | 67.81M |
| Revenue (ttm) | 12.00M |
| Net Income (ttm) | -14.77M |
| Shares Out | 33.57M |
| EPS (ttm) | -0.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,203 |
| Open | 2.03 |
| Previous Close | 2.02 |
| Day's Range | 1.98 - 2.06 |
| 52-Week Range | 1.83 - 6.63 |
| Beta | 2.08 |
| Analysts | Buy |
| Price Target | 14.96 (+640.6%) |
| Earnings Date | May 12, 2022 |
About EYEN
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydria...
Financial Performance
In 2021, Eyenovia's revenue was $14.00 million, an increase of 600.00% compared to the previous year's $2.00 million. Losses were -$12.78 million, -35.36% less than in 2020.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for EYEN stock is "Buy." The 12-month stock price forecast is 14.96, which is an increase of 640.59% from the latest price.
News
Eyenovia Reports First Quarter 2022 Financial Results
Mydcombi™ NDA resubmission on track for Q3 2022
Eyenovia to Report First Quarter 2022 Results on Thursday, May 12
Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day
Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refra...
Presentation to review historic issues related to glaucoma therapies and how these may be addressed through the use of Optejet® technology Presentation to review historic issues related to glaucoma ther...
Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
Results of “SPEED” study confirm the speed of diagnostic effectiveness of a single microdose array print (MAP™) spray using the company's proprietary OpteJet® dispenser Results of “SPEED” study confirm ...
Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results
Successfully completed Type A meeting with FDA and anticipates MydCombi™ NDA resubmission in Q3 2022
Eyenovia to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28
Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day
Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Ce...
Study conducted with Tufts Medical Center represents a breakthrough showing that Microdose Array Print (MAP™) technology can provide similar benefits of non-preserved medications Study conducted with Tu...
Eyenovia Strengthens Balance Sheet with a $15 Million Institutional Capital Investment from Armistice Capital Master ...
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today anno...
8 Penny Stocks To Buy Now According To Insiders In 2022
Penny stocks to buy now according to insiders. The post 8 Penny Stocks To Buy Now According To Insiders In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission
No additional clinical work required; NDA resubmission anticipated in Q3 2022 No additional clinical work required; NDA resubmission anticipated in Q3 2022
Eyenovia Announces Changes to Board of Directors
NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today annou...
Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates
Eyenovia, Inc. (EYEN) delivered earnings and revenue surprises of 11.54% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Eyenovia Reports Third Quarter 2021 Financial Results
On track with VISION-2 phase 3 presbyopia trial and expedited resubmission of MydCombi™ New Drug Application as a drug/device combination in early 2022
Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator@AAO 2021 Meeting
Discussion to Include Future Potential Treatment Options, Including MicroPine (atropine ophthalmic spray), for reduction of myopia progression in pediatrics Discussion to Include Future Potential Treatm...
CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10
Eyenovia will release third quarter 2021 results on Wednesday, November 10, after the close. The prior version of this press release incorrectly stated that third quarter 2021 results would be released ...
Eyenovia to Report Third Quarter 2021 Results on Thursday, November 11
Company to host an investor conference call and webcast at 5:00pm ET on that day Company to host an investor conference call and webcast at 5:00pm ET on that day
Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia
Vision-2 follows successful Vision-1 trial with expected top-line results in Q2 2022
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Eyenovia, Inc. - EYEN
NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eyenovia, Inc. ("Eyenovia" or the "Company") (NASDAQ: EYEN). Such investors are advised to contact...
Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA
Genus Medical Technologies, LLC v. FDA legal case leads to agency-wide review and reclassification of eye cups, eye droppers, and ophthalmic dispensers
Eyenovia (EYEN) Sees Hammer Chart Pattern: Time to Buy?
Eyenovia (EYEN) has been struggling lately, but the selling pressure may be coming to an end soon.
5 Best Penny Stocks To Buy Right Now According To Insiders
5 Penny Stocks Insiders Are Buying Right Now The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Eyenovia Reports Second Quarter 2021 Financial Results
Announced positive topline data from its Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia
Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021
NEW YORK & LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- #ASCRS2021--Eyenovia will participate in a July 22 Eyecelerator@ASCRS panel, entitled, “Presbyopia: Everybody gets it... but can it be fixed?”
Eyenovia to Participate in Two Upcoming Investor Conferences
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array pri...
Eyenovia Stock Shoots Higher on Positive MicroLine Data in Late-Stage Presbyopia Study
Eyenovia Inc (NASDAQ: EYEN) has announced topline data from its VISION-1 Phase 3 study evaluating MicroLine, for the temporary improvement of near vision in adults with presbyopia. The results will be p...